5/19 RegenMD

RegenMD         Shire stages turnaround on latest deal May 18, 2011 at 3:15 PM   By Rachel Cooper, City Reporter 7:10PM BST 18 May 2011 Britain's third-biggest drug maker weakened in morning trading after revealing a $750m (£464m) deal that will take it into the cutting-edge field of regenerative medicine. ... See all stories on this topic »         Klein Makes It Official -- His Last Day is June 23 May 18, 2011 at 1:45 PM         VC biotech bet pays off big May 18, 2011 at 12:16 PM   But today's biggest sale was for a regenerative medicine company tucked inside of Connecticut. Shire PLC (SHPGY) today said that it would pay $750 million in cash to buy Advanced BioHealing Inc., a Westport, Conn.-based regenerative medicine company ... See all stories on this topic »         Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A. May 18, 2011 at 11:22 AM   Its novel macroporous microarchitecture consists of a network of interconnecting cells and pores, creating an environment highly conducive to applications in regenerative medicine, drug discovery, and stem cell research. The unique chemistry and ... See all stories on this topic »         Boston Equity Advisors Acts as Exclusive Agent and Advisor in Histogenics ... May 18, 2011 at 10:15 AM   "This acquisition positions Histogenics with the immediate opportunity to unite tissue engineering technologies with cell therapy technologies to form a very robust portfolio of regenerative medicine technologies, products, intellectual property and ... See all stories on this topic »         Boston Equity Advisors Acts as Exclusive Agent and Advisor in Histogenics ... May 18, 2011 at 9:52 AM   "This acquisition positions Histogenics with the immediate opportunity to unite tissue engineering technologies with cell therapy technologies to form a very robust portfolio of regenerative medicine technologies, products, intellectual property and ... See all stories on this topic »         Shire moves into regenerative medicine with $750m deal May 18, 2011 at 9:52 AM   Shire, Britain's third-largest drug maker, is moving into regenerative medicine with a deal to buy an American biotech business for $750m (£460m) in cash. By Rachel Cooper 11:12AM BST 18 May 2011 Late on Tuesday, Shire said it planned to buy ... See all stories on this topic »         AM Vitals: Merck and Roche in Hepatitis C Drug Marketing Pact May 18, 2011 at 9:52 AM   Regenerative Medicine Bet: Shire Pharmaceuticals will buy Advanced BioHealing for $750 million in cash, making the biotech the hub of a new regenerative medicine unit, Dow Jones Newswires reports. Advanced BioHealing had planned to go public today to ... See all stories on this topic »         Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and ... May 18, 2011 at 7:40 AM   ... core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated in vitro (tissue engineering). ... See all stories on this topic »         Skin Stem Cells from Mice May Treat Human Blindness May 18, 2011 at 7:07 AM   Dr. Michael J. Young, study leader and head of the Schepens Eye Research Institute's regenerative medicine center, along with Dr. Budd A. Tucker, an assistant professor of Ophthalmology at the University of Iowa, and a team of researchers, ... See all stories on this topic » DailyTech         Undifferentiated human adipose tissue-derived stromal cells induce mandibular bone healing in rats. May 18, 2011 at 6:26 AM   Undifferentiated human adipose tissue-derived stromal cells induce mandibular bone healing in rats. Arch Otolaryngol Head Neck Surg. 2011 May;137(5):463-70 Authors: Parrilla C, Saulnier N, Bernardini C, Patti R, Tartaglione T, Fetoni AR, Pola E, Paludetti G, Michetti F, Lattanzi W To test the osteo-regenerative potential of adipose tissue-derived stromal cells (ATSCs), an attractive human source for tissue engineering, in a rat model of mandibular defect. Human dermal fibroblasts (HDFs) were used as a differentiated cellular control in the study. PMID: 21576557 [PubMed - in process]         Shire to Establish new Regenerative Medicine Business Unit Through Cash ... May 18, 2011 at 3:56 AM   By Shire plc Reader comments on Sacbee.com are the opinions of the writer, not The Sacramento Bee. If you see an objectionable comment, click the flag icon below it. We will delete comments containing inappropriate links, obscenities, hate speech, ... See all stories on this topic »         Southern California Investor Identified as Possible Candidate for CIRM Chair May 18, 2011 at 3:21 AM         Morning news summary: Shire, Rio Tinto, Petrofac, Amec, Victoria Oil & Gas ... May 18, 2011 at 3:01 AM   Shire (LON:SHP) is set to establish a new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc., including US marketed DERMAGRAFT. The purchase price is US$750 million in cash, financed from Shire's existing cash ... See all stories on this topic » Proactive Investors UK             This email was sent to regenmd@gmail.com. Delivered by Feed My Inbox PO Box 682532 Franklin, TN 37068 Account Login Unsubscribe Here